MetaCap

Bicara Therapeutics (BCAX) vs Design Therapeutics (DSGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Design Therapeutics (DSGN) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 8.0% versus a loss of 53.2%. Design Therapeutics is the larger company by market cap ($577.6 million vs $560.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCAX-53.22%DSGN+8.02%
+98%+17%-63%
Nov 21, 20251 yearNov 20, 2026
BCAX-63.95%DSGN+62.82%
+195%+59%-76%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCAX versus DSGN key metrics
MetricBCAXDSGN
Share price$8.44$9.02
Market cap$560.31M$577.61M
1-day change-7.46%-3.22%
YTD return-49.85%-3.84%
1-year return-53.22%+8.02%
5-year return—-49.27%
EPS (TTM)$-3.46$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-137.95M$-69.79M
52-week high$30.99$17.25
52-week low$7.87$8.21
Distance from 52-week high-72.77%-47.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+281.16%+139.14%
Average volume1.20M554.69K
Shares outstanding66.39M64.04M
Employees10360
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DSGN has outperformed BCAX by 61.2 percentage points over the past year.

About Bicara Therapeutics

BCAX stock →

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees

About Design Therapeutics

DSGN stock →

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

BCAX vs DSGN FAQ

Which is bigger, Bicara Therapeutics or Design Therapeutics?

Design Therapeutics (DSGN) is larger, with a market capitalization of $577.61M compared with $560.31M for Bicara Therapeutics (BCAX).

Which stock has performed better over the past year, BCAX or DSGN?

DSGN returned +8.02% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.

Are Bicara Therapeutics and Design Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons